Moderna's Vaccine Portfolio Primed For Boost From Its COVID-19 Work

At its "Vaccines Day" with investors, Moderna execs tout the company's messenger RNA platform and say its portfolio of vaccine candidates has the potential to reach annual peak sales of up to $12bn.

Stone / United Kingdom - February 11 2020: Moderna medical compamy logo seen on the brochure with the viral masks, syringe and pills. Photo concept. Selective focus.
Moderna touts its messenger RNA and vaccines pipline to investors

Moderna Inc.'s rapid advancement of a vaccine candidate for COVID-19 into clinical trials may help the company establish its messenger RNA platform and advance work on other vaccines in its pipeline.

Executives showcased Moderna's mRNA technology and its potential advantages at a 14 April "Vaccines Day" with investors. CEO Stéphane Bancel...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip